News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
287,392 Results
Type
Article (22202)
Company Profile (133)
Press Release (265046)
Multimedia
Podcasts (57)
Webinars (19)
Section
Business (84209)
Career Advice (843)
Deals (13498)
Drug Delivery (87)
Drug Development (28149)
Employer Resources (147)
FDA (5443)
Job Trends (7024)
News (132337)
Policy (10587)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1606)
Academic (2)
Accelerated approval (17)
Adcomms (17)
Allergies (60)
Alliances (24950)
ALS (80)
Alzheimer's disease (874)
Antibody-drug conjugate (ADC) (267)
Approvals (5683)
Artificial intelligence (396)
Autoimmune disease (132)
Automation (33)
Bankruptcy (71)
Best Places to Work (5649)
BIOSECURE Act (13)
Biosimilars (127)
Biotechnology (84)
Bladder cancer (89)
Brain cancer (27)
Breast cancer (326)
Cancer (2556)
Cardiovascular disease (214)
Career advice (764)
Career pathing (40)
CAR-T (181)
CDC (26)
Cell therapy (451)
Cervical cancer (18)
Clinical research (24114)
Collaboration (1288)
Compensation (273)
Complete response letters (27)
COVID-19 (1255)
CRISPR (66)
C-suite (677)
Cystic fibrosis (68)
Data (3377)
Decentralized trials (2)
Denatured (25)
Depression (66)
Dermatology (34)
Diabetes (235)
Diagnostics (3378)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (38)
Drug discovery (210)
Drug pricing (66)
Drug shortages (5)
Duchenne muscular dystrophy (132)
Earnings (25065)
Editorial (26)
Employer branding (23)
Employer resources (124)
Events (41682)
Executive appointments (679)
FDA (7018)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (7)
Frontotemporal dementia (9)
Funding (1017)
Gene editing (130)
Generative AI (39)
Gene therapy (308)
GLP-1 (510)
Government (1643)
Grass and pollen (1)
Guidances (178)
Healthcare (6588)
HIV (44)
Huntington's disease (28)
IgA nephropathy (41)
Immunology and inflammation (94)
Immuno-oncology (41)
Indications (64)
Infectious disease (1415)
Inflammatory bowel disease (118)
Inflation Reduction Act (9)
Influenza (70)
Intellectual property (131)
Interviews (119)
IPO (5451)
IRA (17)
Job creations (1538)
Job search strategy (647)
JPM (36)
Kidney cancer (6)
Labor market (88)
Layoffs (233)
Leadership (22)
Legal (2096)
Liver cancer (52)
Longevity (16)
Lung cancer (346)
Lymphoma (221)
Machine learning (31)
Management (43)
Manufacturing (529)
MASH (57)
Medical device (4176)
Medtech (4208)
Mergers & acquisitions (8689)
Metabolic disorders (621)
mRNA (82)
Multiple sclerosis (103)
NASH (10)
Neurodegenerative disease (188)
Neuropsychiatric disorders (37)
Neuroscience (1552)
Neurotech (1)
NextGen: Class of 2026 (2427)
Non-profit (1780)
Now hiring (73)
Obesity (322)
Opinion (147)
Ovarian cancer (80)
Pain (109)
Pancreatic cancer (99)
Parkinson's disease (169)
Partnered (24)
Patents (236)
Patient recruitment (262)
Peanut (18)
People (32127)
Pharmaceutical (26)
Pharmacy benefit managers (7)
Phase 1 (7465)
Phase 2 (10208)
Phase 3 (8815)
Pipeline (3465)
Policy (119)
Postmarket research (779)
Preclinical (3688)
Press Release (62)
Prostate cancer (112)
Psychedelics (27)
Radiopharmaceuticals (137)
Rare diseases (406)
Real estate (3041)
Recruiting (59)
Regulatory (8919)
Reports (53)
Research institute (1430)
Resumes & cover letters (109)
Rett syndrome (8)
RNA editing (14)
RSV (50)
Schizophrenia (84)
Series A (201)
Series B (131)
Service/supplier (7)
Sickle cell disease (49)
Special edition (13)
Spinal muscular atrophy (71)
Sponsored (20)
Startups (2314)
State (1)
Stomach cancer (8)
Supply chain (54)
Tariffs (22)
The Weekly (31)
Vaccines (462)
Venture capital (82)
Weight loss (195)
Women's health (54)
Worklife (19)
Date
Last 7 days (328)
Last 30 days (1282)
Last 365 days (14394)
2026 (4006)
2025 (14195)
2024 (15959)
2023 (18009)
2022 (23932)
2021 (26128)
2020 (23352)
2019 (18787)
2018 (13862)
2017 (13775)
2016 (13206)
2015 (14774)
2014 (10826)
2013 (9274)
2012 (9743)
2011 (10044)
2010 (9396)
Location
Africa (397)
Alabama (42)
Alaska (4)
Arizona (121)
Arkansas (6)
Asia (30514)
Australia (4039)
California (5413)
Canada (1649)
China (819)
Colorado (212)
Connecticut (171)
Delaware (215)
Europe (41671)
Florida (751)
Georgia (139)
Hawaii (3)
Idaho (17)
Illinois (318)
India (64)
Indiana (330)
Iowa (12)
Japan (407)
Kansas (95)
Kentucky (16)
Louisiana (14)
Maine (13)
Maryland (612)
Massachusetts (4125)
Michigan (166)
Minnesota (234)
Mississippi (5)
Missouri (59)
Montana (9)
Nebraska (12)
Nevada (40)
New Hampshire (25)
New Jersey (1572)
New Mexico (20)
New York (1606)
North Carolina (707)
North Dakota (9)
Northern California (2837)
Ohio (195)
Oklahoma (12)
Oregon (22)
Pennsylvania (766)
Puerto Rico (9)
Rhode Island (19)
South America (480)
South Carolina (15)
Southern California (1919)
Tennessee (86)
Texas (809)
United States (19011)
Utah (116)
Vermont (1)
Virginia (149)
Washington D.C. (37)
Washington State (411)
West Virginia (1)
Wisconsin (101)
Wyoming (1)
287,392 Results for "nextgen sciences ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III
While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.
February 3, 2026
·
2 min read
·
Tristan Manalac
NextGen
BioSpace
’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics,
BioSpace
’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
February 18, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
March 25, 2026
·
8 min read
Venture capital
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.
March 18, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
March 3, 2026
·
4 min read
·
Nick Paul Taylor
Press Releases
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
March 5, 2026
·
3 min read
Antibody-drug conjugate (ADC)
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.
February 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms
March 18, 2026
·
1 min read
Press Releases
NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review
December 12, 2025
·
2 min read
1 of 28,740
Next
